I currently lead the US Neurology Business Unit at Alexion, AstraZeneca 罕见的疾病. The neurology business unit is responsible for assets in gMG (generalized Myasthenia Gravis) 和 NMOSD (Neuromuscular Optica Spectrum Disorder). As part of my remit, 我负责澳门葡京赌博游戏的销售, thought leader liaison 和 marketing teams across all approved assets in addition to a team that works closely with our global colleagues to ensure launch readiness for late stage neurology pipeline assets. We are a business unit that is four years young 和 has accomplished much in our short time. Our mission is to deliver life-altering therapies to our patients today 和 help fund the development of future assets in our rare disease pipeline.
I have a BS in biology from Providence College. Before joining Alexion, I worked for Biogen 和 have run businesses (和 Br和s) for them in the US 和 Europe where I launched four products in neurology, including Multiple Sclerosis. In my last role at Biogen, I was the General Manager of the Canadian Business. 在这个角色中, I spun off Bioverativ, launched a new product in MS, 和 built out their ultra-rare business model for Spinal Muscular Atrophy.
在我的职业生涯中, I have also worked in consumer products for Colgate Palmolive leading their US 和 North American marketing business.
I am a big believer in mentoring 和 continue to mentor (和 be mentored by) many of my current 和 former colleagues.
There is nothing more rewarding than working cross-functionally to help patients gain access to our therapies 和 then see how that therapy can dramatically change their 和 their loved ones' quality of life. That is rare disease!
Colgate Palmolive Chairman Award
生原体首席执行官
2021
电流的作用
2016
2013
Veeva ID: Z4-62681
Date of preparation: March 2024